From Bench to Bedside: The Story of CoreTag’s Targeted Radiotherapy & First In-Human Trial Results
Time: 11:00 am
day: Conference Day Two
Details:
- Exploring the discovery and development of CoreTags lead targeted radiopharmaceutical asset, and challenges in early development
- Progressing the candidate through preclinical development and translating results into the clinic; what were the major concerns preclinically and how to overcomet ranslational bottlenecks?
- Overcoming manufacturing hurdles and revealing data from our first in human clinical trial: what is next for CoreTag?
